Hansa Biopharma Dirección

Dirección controles de criterios 2/4

El CEO de Hansa Biopharma es Søren Tulstrup , nombrado en Mar 2018, tiene una permanencia de 6.67 años. compensación anual total es SEK27.51M, compuesta por 30.7% salario y 69.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.085% de las acciones de la empresa, por valor de SEK1.77M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 3.5 años, respectivamente.

Información clave

Søren Tulstrup

Chief Executive Officer (CEO)

SEK 27.5m

Compensación total

Porcentaje del salario del CEO	30.7%
Permanencia del CEO	6.7yrs
Participación del CEO	0.08%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Søren Tulstrup en comparación con los beneficios de Hansa Biopharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 655m
Jun 30 2024	n/a	n/a	-SEK 802m
Mar 31 2024	n/a	n/a	-SEK 845m
Dec 31 2023	SEK 28m	SEK 8m	-SEK 832m
Sep 30 2023	n/a	n/a	-SEK 856m
Jun 30 2023	n/a	n/a	-SEK 759m
Mar 31 2023	n/a	n/a	-SEK 678m
Dec 31 2022	SEK 26m	SEK 8m	-SEK 611m
Sep 30 2022	n/a	n/a	-SEK 626m
Jun 30 2022	n/a	n/a	-SEK 620m
Mar 31 2022	n/a	n/a	-SEK 583m
Dec 31 2021	SEK 26m	SEK 7m	-SEK 548m
Sep 30 2021	n/a	n/a	-SEK 491m
Jun 30 2021	n/a	n/a	-SEK 465m
Mar 31 2021	n/a	n/a	-SEK 431m
Dec 31 2020	SEK 21m	SEK 6m	-SEK 421m
Sep 30 2020	n/a	n/a	-SEK 426m
Jun 30 2020	n/a	n/a	-SEK 398m
Mar 31 2020	n/a	n/a	-SEK 381m
Dec 31 2019	SEK 11m	SEK 5m	-SEK 360m
Sep 30 2019	n/a	n/a	-SEK 330m
Jun 30 2019	n/a	n/a	-SEK 298m
Mar 31 2019	n/a	n/a	-SEK 274m
Dec 31 2018	SEK 8m	SEK 4m	-SEK 248m

Compensación vs. Mercado: La compensación total de Søren($USD2.49M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD736.31K).

Compensación vs. Ingresos: La compensación de Søren ha aumentado mientras la empresa no es rentable.

CEO

Søren Tulstrup (59 yo)

6.7yrs

Permanencia

SEK 27,505,000

Compensación

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Søren Tulstrup	President & CEO	6.7yrs	SEK 27.51m	0.085% SEK 1.8m
C. Ballantyne	Chief Financial Officer	less than a year	sin datos	sin datos
Christian Kjellman	Senior VP & COO	4.8yrs	sin datos	sin datos
Hitto Kaufmann	Chief Scientific and R&D Officer	less than a year	sin datos	sin datos
Eva-Maria Joed	Vice President of Finance & Administration	5.5yrs	sin datos	sin datos
Klaus Sindahl	VP & Head of Investor Relations	no data	sin datos	sin datos
Anne Lanner	Senior VP & Chief Human Resources Officer	5.8yrs	sin datos	sin datos
Emanuel Björne	VP & Head of Business Development	no data	sin datos	sin datos
Lena Winstedt	Head of Science	no data	sin datos	sin datos
Vincenza Nigro	VP & Head of Medical Affairs	no data	sin datos	sin datos
Magnus Korsgren	VP & Head of Research and Development	3.6yrs	sin datos	sin datos

4.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0RC7 se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Florian Nicolas Reinaud	Director	less than a year	sin datos	sin datos
Anders Pedersen	Independent Director	6.5yrs	SEK 413.00k	0.0037% SEK 76.8k
Mats Blom	Independent Director	5.5yrs	SEK 493.00k	0.0015% SEK 30.6k
Peter Nicklin	Independent Chairman of the Board	2.4yrs	SEK 1.14m	0.036% SEK 751.7k
Eva Nilsagard	Independent Director	5.5yrs	SEK 591.00k	0.0044% SEK 92.0k
Hilary Malone	Independent Director	3.5yrs	SEK 725.00k	sin datos
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	sin datos	sin datos
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	sin datos	sin datos
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	sin datos	sin datos
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	sin datos	sin datos
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	sin datos	sin datos
Jonas Wikstrom	Director	less than a year	sin datos	sin datos

3.5yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RC7 se considera experimentada (3.5 años de antigüedad promedio).

Hansa Biopharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Recent updates

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Third quarter 2024 earnings released: kr1.53 loss per share (vs kr4.78 loss in 3Q 2023)

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Second quarter 2024 earnings released: kr3.30 loss per share (vs kr4.79 loss in 2Q 2023)

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022)

New minor risk - Profitability

New minor risk - Profitability

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022)

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

New minor risk - Share price stability

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022)

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

Senior VP recently bought kr346k worth of stock

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Insider recently bought kr58k worth of stock

First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021)

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020)

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)

Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients